Background And Aim: Notwithstanding multiple recommendations in guidelines, percutaneous endoscopic gastrostomy (PEG)-tube placement is still performed in patients with dementia. In this study, we aim to investigate survival in patients with and without dementia after PEG-tube placement.
Methods: We conducted a retrospective multicenter study in four different hospitals in the Netherlands. Furthermore, we explored the ethical considerations that may play a role in the decision whether or not to insert a PEG tube in a patient with dementia.
Results: Three-hundred-and-three patients were included, mean age of 77.4 years. Forty-two (13.9%) patients had dementia. Short-term complications did not differ between patients with and without cognitive disorders (P 0.224). However, patients with dementia survived significantly shorter after PEG placement than did patients without dementia. Adjusted for age and sex, patients with dementia had a 49% increased risk of mortality (hazard ratio 1.49, 95% confidence interval 1.01-2.19). In our exploratory literature search, we found that several ethical concerns and considerations play a role in the decision process of PEG placement. These considerations are both medical and nonmedical and include beliefs regarding the benefits of a PEG tube, a lack of knowledge about the natural course of dementia in both professionals and family of patients, and a fear of letting a patient die hungry.
Conclusions: Patients with dementia had higher mortality rates after PEG placement than patients without dementia. Although multiple ethical concerns and considerations play a role, insertion of a PEG tube in patients with dementia is not appropriate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jgh.14573 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of sensory impairment in older adults with dementia.
J Otol
October 2024
Department of Public Health, Faculty of Medicine and Dentistry, Palacký University Olomouc, Czech Republic.
Background: Over 55 million people worldwide are living with dementia. The rate of cognitive decline increases with age, and loss of senses may be a contributing factor.
Objectives: This study aimed to analyze hearing, olfactory function, and color vision in patients with dementia.
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
Alzheimers Dement
January 2025
Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Introduction: The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET.
Methods: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered.
Plasma p-tau and neurofilament/p-tau ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration.
Alzheimers Dement
January 2025
Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Introduction: Plasma-based biomarkers have shown promise for clinical implementation, but their accuracy in differentiating Alzheimer's disease (AD) from syndromes associated with frontotemporal lobar degeneration (FTLD) has yet to be fully investigated. This study assessed the potential of plasma biomarkers for differential diagnosis.
Methods: This cohort study included 374 participants (96 AD, 278 FTLD).
Clinical 7 Tesla magnetic resonance imaging: Impact and patient value in neurological disorders.
J Intern Med
January 2025
Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden.
Magnetic resonance imaging (MRI) is a cornerstone of non-invasive diagnostics and treatment monitoring, particularly for diseases of the central nervous system. Although 1.5- and 3 Tesla (T) field strengths remain the clinical standard, the advent of 7 T MRI represents a transformative step forward, offering superior spatial resolution, contrast, and sensitivity for visualizing neuroanatomy, metabolism, and function.
View Article and Find Full Text PDFDevelopment and Validation of a Tool to Predict Onset of Mild Cognitive Impairment and Alzheimer Dementia.
JAMA Netw Open
January 2025
The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.
Importance: The ability to predict the onset of mild cognitive impairment (MCI) and Alzheimer dementia (AD) could allow older adults and clinicians to make informed decisions about dementia care.
Objective: To assess whether the age at onset of MCI and AD can be predicted using a statistical modeling approach.
Design, Setting, And Participants: This prognostic study used data from 2 aging and dementia cohort studies-the Australian Imaging, Biomarker and Lifestyle (AIBL) study and the Alzheimer's Disease Neuroimaging Initiative (ADNI)-for model development and validation of the Florey Dementia Index (FDI), a tool used to predict the age at onset of MCI and AD in older adults.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!